(Q40413987)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15957512%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

title

Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15957512%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15957512%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Mar Tintoré

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15957512%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

María Jesús Arévalo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15957512%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Xavier Montalban

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15957512%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

author name string

Joana Porcel

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15957512%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Nieves Téllez

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15957512%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Angela Sánchez-Betancourt

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15957512%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Carlos Nos

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15957512%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

publication date

1 June 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15957512%20AND%20SRC:MED&resulttype=core&format=json

Multiple Sclerosis Journal

12 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15957512%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15957512%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15957512%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

page(s)

306-309

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15957512%20AND%20SRC:MED&resulttype=core&format=json

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

12 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1173OA

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1173OA

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1173OA

Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1173OA

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1173OA

Side effect profile of interferon beta-1b in MS: results of an open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1173OA

Long-term and short-term outcome of multiple sclerosis: a 3-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1173OA

A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1173OA

Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1173OA

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1173OA

10.1191/1352458505MS1173OA

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15957512%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference